Vor Biopharma (NYSE:VOR) Stock Price Down 8.6% Following Insider Selling

Key Points

• Vor Biopharma's stock plummeted 8.6% to $27.80 following significant insider selling by major shareholder Reprogrammed Interchange LLC.
• Insider transactions included sales of over 1.1 million shares at prices averaging from $1.54 to $1.75, resulting in a decrease in their overall position by 1.35%.
• Despite the recent drop, analysts maintain a generally positive outlook with five "Buy" ratings and a price target average of $6.07.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report)'s stock price dropped 8.6% during trading on Friday after an insider sold shares in the company. The company traded as low as $27.73 and last traded at $27.80. Approximately 108,721 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 377,381 shares. The stock had previously closed at $30.40.

Specifically, major shareholder Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $1.54, for a total value of $688,808.12. Following the transaction, the insider owned 32,781,209 shares in the company, valued at $50,483,061.86. This trade represents a 1.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $30.80, for a total transaction of $688,780.40. Following the completion of the transaction, the insider owned 1,639,060 shares in the company, valued at $50,483,048. This trade represents a 1.35% decrease in their position. The disclosure for this sale can be found here. In other news, major shareholder Reprogrammed Interchange Llc sold 20,000 shares of the firm's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $32.80, for a total value of $656,000.00. Following the sale, the insider directly owned 1,661,424 shares of the company's stock, valued at approximately $54,494,707.20. This trade represents a 1.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on VOR shares. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. HC Wainwright reiterated a "buy" rating and set a $60.00 price target on shares of Vor Biopharma in a report on Thursday, August 14th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $121.33.

Vor Biopharma Stock Performance

The stock has a 50-day simple moving average of $39.97 and a 200 day simple moving average of $22.99. The company has a market cap of $195.48 million, a P/E ratio of -18.85 and a beta of 2.05.

Institutional Trading of Vor Biopharma

Several institutional investors have recently made changes to their positions in the business. Two Sigma Investments LP boosted its position in shares of Vor Biopharma by 18.9% during the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after acquiring an additional 25,930 shares in the last quarter. Money Concepts Capital Corp lifted its stake in Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares during the period. XTX Topco Ltd acquired a new position in shares of Vor Biopharma in the 2nd quarter worth approximately $66,000. Northern Trust Corp raised its holdings in shares of Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after buying an additional 44,252 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after buying an additional 58,247 shares in the last quarter. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.